RA Capital Management’s Nektar Therapeutics NKTR Stock Holding History

RA Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,246,667	Closed	-$11.1M	–	67
2023 Q3	$11.1M	Buy	+1,246,667	New	+$12M	0.22%	53
2016 Q4	–	Sell	-244,277	Closed	-$63M	–	31
2016 Q3	$63M	Buy	244,277 +29,287	+14%	+$7.54M	6.49%	6
2016 Q2	$45.9M	Buy	214,990 +3,066	+1%	+$685K	6.35%	6
2016 Q1	$43.7M	Buy	+211,924	New	+$40.7M	5.59%	5

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RA Capital Management's NKTR Position: Q4 2023 in Review

RA Capital Management sold out of Nektar Therapeutics (NKTR) in Q4 2023, closing a stake of 1,246,667 shares — an estimated $11.1M sold.

RA Capital Management first reported a position in NKTR in Q1 2016 and held it in 4 quarters. The position peaked at $63M in Q3 2016. 125 funds tracked by Wall St. Rank hold NKTR as of Q4 2023.

RA Capital Management reported no remaining Nektar Therapeutics position as of Q4 2023 after selling out during the quarter.
RA Capital Management sold 1,246,667 Nektar Therapeutics shares in Q4 2023, an estimated $11.1M.
RA Capital Management first reported a position in Nektar Therapeutics in Q1 2016 and held it in 4 quarters.
RA Capital Management's Nektar Therapeutics position peaked at $63M in Q3 2016.
125 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2023.

Based on RA Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.